ArticleAmerican journal of translational research2026
Ulinastatin-somatostatin combination for acute severe pancreatitis: enhanced clinical efficacy and reduced serum inflammation.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the clinical effect of ulinastatin (UTI)-somatostatin (SS) combination on acute severe pancreatitis (SAP) patients, focusing on changes in efficacy and serum inflammatory markers (IMs).
methodsThis study retrospectively enrolled 104 SAP patients (July 2022-July 2025), with 51 patients (control group) treated with SS and 53 cases (observation group) receiving UTI+SS. Clinical efficacy, safety (rash, dizziness, diarrhea, nausea/vomiting, kidney injury, hyperglycemia), symptom relief time (vomiting, pyrexia, celialgia, defecation recovery, abdominal distension), disease-related indicators (blood amylase [AMS], Acute Physiology And Chronic Health Evaluation II [APACHE-II]), pancreatic function (insulin [INS], trypsinogen-2 [TPS2], glucose [Glu]), serum IMs (C-reactive protein [CRP], tumor necrosis factor [TNF]-α, interleukin [IL]-6), intestinal mucosal barrier function (diamine oxidase [DAO], D-lactic acid [D-Lac], endotoxin [ET]), laboratory-related indexes (total white blood cell count [WBC], platelet count [PLT], creatinine [Cr], total bilirubin [TBIL]), and humoral immunity (immunoglobulin [Ig] A/M/G) were comparatively assessed. Finally, determinants of patients' therapeutic effects were isolated by uni- and multivariate analyses.
resultsUTI+SS was markedly superior to sole SS in terms of overall effectiveness, INS, PLT, and IgA/M/G, along with faster symptom relief, lower AMS, APACHE-II scores, TPS2, Glu, CRP, TNF-α, IL-6, DAO, D-Lac, WBC, Cr, and TBIL. Total adverse reaction incidence showed no notable inter-group difference. CRP and Cr were independent risk factors for therapeutic efficacy among SAP patients, while treatment modality acted as an independent protective factor.
conclusionUTI+SS for SAP is effective in clinical efficacy enhancement and serum inflammation suppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.